Industry Voices—The beginning of the end for Alzheimer’s Dementia?
Fierce Healthcare
OCTOBER 26, 2023
The approval of Leqembi by the Food and Drug Administration marks an exciting turning point for Alzheimer’s disease. | The approval of Leqembi by the FDA marks an exciting turning point for Alzheimer’s disease. There are big questions around costs, access, risk and efficacy in certain populations. The most urgent, overarching question is: How can we find patients who will benefit from the drug before their condition progresses outside of the treatment window?
Let's personalize your content